The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Measured by its ability to inhibit TNFa mediated cytotoxicity in L-929 mouse fibroblast cells in the presence of the metabolic inhibitor actinomycin D.
The ED50 for this effect is typically 0.05-0.5 µg/mL in the presence of 0.25 ng/mL recombinant Human TNFa.
< 1.000 Eu/µg
>95% by SDS-PAGE .
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped at 4°C. After reconstitution store at -20ºC. Avoid freeze / thaw cycles.
pH: 7.40 Constituent: 95% PBS Note: 5-10% trehalose is commonly used for freeze drying, and after reconstitution, the trehalose is mostly about 3-5%
This product is an active protein and may elicit a biological response in vivo, handle with caution.
It is recommended to reconstitute the lyophilized protein in sterile deionized water to a final concentration of 400 µg/ml. Solubilize for 30 to 60 minutes at room temperature with occasional gentle mixing. Carrier protein (0.1% HSA or BSA) is strongly recommended for further dilution and long term storage.
p75 TNF receptor
p80 TNF alpha receptor
p80 TNF-alpha receptor
Soluble TNFR1B variant 1
TNF R II
Tumor necrosis factor beta receptor
Tumor necrosis factor binding protein 2
Tumor necrosis factor receptor 2
Tumor necrosis factor receptor superfamily member 1B
Tumor necrosis factor receptor type II
Tumor necrosis factor-binding protein 2
Receptor with high affinity for TNFSF2/TNF-alpha and approximately 5-fold lower affinity for homotrimeric TNFSF1/lymphotoxin-alpha. The TRAF1/TRAF2 complex recruits the apoptotic suppressors BIRC2 and BIRC3 to TNFRSF1B/TNFR2. This receptor mediates most of the metabolic effects of TNF-alpha. Isoform 2 blocks TNF-alpha-induced apoptosis, which suggests that it regulates TNF-alpha function by antagonizing its biological activity.
Contains 4 TNFR-Cys repeats.
Phosphorylated; mainly on serine residues and with a very low level on threonine residues. A soluble form (tumor necrosis factor binding protein 2) is produced from the membrane form by proteolytic processing.